好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal follow-up of dual-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor
Movement Disorders
P4 - Poster Session 4 (5:30 PM-6:30 PM)
10-044
To report longitudinal outcomes of tremor improvement in patients with medically refractory MS tremor. 

Multiple Sclerosis (MS) tremor is typically pharmacoresistant and disabling.

Studies of treatment outcomes with stereotactic lesioning or single-lead deep brain stimulation (DBS) have been variable. Dual-lead thalamic DBS targeting the ventralis intermedius (VIM) and ventralis oralis (VO) has been shown to be a safe and effective therapy. Currently there is limited data on long-term outcomes of dual-lead thalamic DBS for tremor management. We report long-term outcomes in a cohort of patients with medically refractory MS tremor treated with dual-lead thalamic DBS.

Retrospective review of 19 patients with medically refractory tremor who underwent dual-lead thalamic DBS from 2007-2015. In this study 15 patients were included who were evaluated using the Tolosa-Fahn-Marin Tremor Rating Scale (TRS) before surgery and on-stimulation at 1, 3, and 5 years postoperatively.

Median total TRS scores improved from baseline during a five-year follow-up

(p=0.026). Median TRS motor scores were reduced from baseline during this period (p=0.044). No statistically significant differences were found in TRS activities of daily living (ADL) scores postoperatively compared to pre-surgical baseline (p=0.212).

Dual-lead thalamic DBS is potentially an effective treatment for the long-term

improvement of severe, medication refractory tremor in MS. Although there is an improvement in motor scores, the disability questionnaire components remained unchanged from baseline, this may be related to disability due to underlying ataxia. 
Authors/Disclosures
Bhavana U. Patel, DO (Bhavana Patel)
PRESENTER 		The institution of Dr. Patel has received research support from National Institute on Aging. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Question writer with 好色先生.
Ryan P. Barmore, MD (Ryan Barmore) No disclosure on file
Ahmad El Kouzi, MD, FAAN Dr. El Kouzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie.
No disclosure on file
Leonardo Almeida (University of Florida College of Medicine - Neurology) No disclosure on file
Kelly D. Foote, MD Kelly D. Foote, MD has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axio/Neurocrine Biosciences.
Michael S. Okun, MD, FAAN (University of Florida) Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.